279 related articles for article (PubMed ID: 1282631)
21. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet.
Becker RH; Wiemer G; Linz W
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S110-5. PubMed ID: 1725017
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
Hecker M; Pörsti I; Busse R
Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
[TBL] [Abstract][Full Text] [Related]
23. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed.
Lamontagne D; König A; Bassenge E; Busse R
J Cardiovasc Pharmacol; 1992 Oct; 20(4):652-7. PubMed ID: 1280723
[TBL] [Abstract][Full Text] [Related]
24. ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries.
Gauthier KM; Cepura CJ; Campbell WB
Biol Chem; 2013 Sep; 394(9):1205-12. PubMed ID: 23729620
[TBL] [Abstract][Full Text] [Related]
25. Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells.
Lückhoff A; Pohl U; Mülsch A; Busse R
Br J Pharmacol; 1988 Sep; 95(1):189-96. PubMed ID: 3064851
[TBL] [Abstract][Full Text] [Related]
26. Differential control and calcium-dependence of production of endothelium-derived relaxing factor and prostacyclin by pig aortic endothelial cells.
White DG; Martin W
Br J Pharmacol; 1989 Jul; 97(3):683-90. PubMed ID: 2547481
[TBL] [Abstract][Full Text] [Related]
27. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor.
Pörsti I; Bara AT; Busse R; Hecker M
Br J Pharmacol; 1994 Mar; 111(3):652-4. PubMed ID: 8019744
[TBL] [Abstract][Full Text] [Related]
28. Endothelium-mediated vasodilation during ACE inhibition.
Auch-Schwelk W; Duske E; Claus M; Graf K; Gräfe M; Fleck E
Eur Heart J; 1995 May; 16 Suppl C():59-65. PubMed ID: 7556274
[TBL] [Abstract][Full Text] [Related]
29. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation.
Bauersachs J; Hecker M; Busse R
Br J Pharmacol; 1994 Dec; 113(4):1548-53. PubMed ID: 7889312
[TBL] [Abstract][Full Text] [Related]
30. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals.
Hecker M; Bara AT; Bauersachs J; Busse R
J Physiol; 1994 Dec; 481 ( Pt 2)(Pt 2):407-14. PubMed ID: 7738833
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the angiotensin converting enzyme by perindoprilat and release of nitric oxide.
Desta B; Vanhoutte PM; Boulanger CM
Am J Hypertens; 1995 May; 8(5 Pt 2):1S-6S. PubMed ID: 7544135
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin D2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation.
Braun M; Schrör K
Circ Res; 1992 Dec; 71(6):1305-13. PubMed ID: 1385004
[TBL] [Abstract][Full Text] [Related]
33. Effects of bradykinin in the rat isolated perfused heart: role of kinin receptors and endothelium-derived relaxing factor.
Baydoun AR; Woodward B
Br J Pharmacol; 1991 Jul; 103(3):1829-33. PubMed ID: 1657268
[TBL] [Abstract][Full Text] [Related]
34. Coronary endothelium is responsive to bradykinin and arachidonate but not to acetylcholine.
Harasawa Y; Kimura M; Ohno Y; Hayashi S
Arch Int Pharmacodyn Ther; 1989; 302():196-208. PubMed ID: 2517685
[TBL] [Abstract][Full Text] [Related]
35. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta.
Berkenboom G; Brékine D; Unger P; Grosfils K; Staroukine M; Fontaine J
Hypertension; 1995 Nov; 26(5):738-43. PubMed ID: 7591012
[TBL] [Abstract][Full Text] [Related]
36. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism.
Zanzinger J; Zheng X; Bassenge E
Cardiovasc Res; 1994 Feb; 28(2):209-14. PubMed ID: 8143302
[TBL] [Abstract][Full Text] [Related]
37. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
Linz W; Wiemer G; Schölkens BA
Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
[TBL] [Abstract][Full Text] [Related]
38. Converting-enzyme inhibitors potentiate bradykinin-induced relaxation in vitro.
Félétou M; Germain M; Teisseire B
Am J Physiol; 1992 Mar; 262(3 Pt 2):H839-45. PubMed ID: 1558194
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
Ehring T; Baumgart D; Krajcar M; Hümmelgen M; Kompa S; Heusch G
Circulation; 1994 Sep; 90(3):1368-85. PubMed ID: 8087948
[TBL] [Abstract][Full Text] [Related]
40. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
Busse R; Hecker M
Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
